Edwards Lifesciences Corporation EW NYSE

Edwards Lifesciences Corporation (EW) generated $450.9M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $97.4M, free cash flow was $353.5M.

Free cash flow margin was 22.5% of revenue. Cash conversion ratio was 4.94x, indicating earnings are backed by cash.

The company returned $40.6M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (76/100, Pass) — $353.5M (22.5% margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 4.94x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 74/100 with 6/7 criteria passed.